ARTICLE | Company News
iCo, Immune Pharmaceuticals deal
December 13, 2010 8:00 AM UTC
iCo granted Immune Pharmaceuticals an option to license exclusive, worldwide rights to iCo-008 for systemic uses. iCo, which will receive an undisclosed option fee creditable upon conversion against ...